Cox univariate analyses and Cox multivariate analyses for different factors
A total of 65 out of 127 patients with treated metastatic advanced colorectal cancer who received immune checkpoint inhibitors were followed up. Age (≤60 vs. >60), gender (Female vs. Male), tumor site (Left colon vs. Right colon), MMR (pMMR vs. dMMR), KRAS status (KRAS mutant vs. KRAS wild), whether combined with targeted therapy (No vs. Yes ), whether liver metastatic cancer (No vs.Yes), whether lymph nodes metastases (No vs.Yes), type of immune checkpoint inhibitor (Domestic vs. Imported), and level of NLR (<3 vs.≥3) were used to perform Cox one-way survival analysis. The results showed that there was a statistically significant difference in PFS between the different groups of patients with MMR status and NLR level factors,P <0.05, and no statistically significant difference in the other factors. The MMR and NLR level factors were then included in Cox multivariate survival analysis, and the results showed that there was a statistically significant difference in the PFS data between the patients in the high NLR group and the low NLR group, P =0.024, which further illustrated that patients with a low NLR who received immune checkpoint inhibitor therapy had a longer PFS and a better prognosis, as shown in Table 5.
Table 5 Cox analyses for different factors